CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TopoTarget A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TopoTarget A/S
c/o Symbion
Fruebjergvej 3, Koebenhavn OE
KOEBENHAVN, 2100  Denmark Ticker: TOPOTOPO
This company was Merged or Acquired on 7/22/2014.
This is a Subsidiary, click here for the Parent Company
Business Summary
Topotarget A/S is a Denmark-based biopharmaceutical company focused on the field of oncology. The Company is engaged in the development of cancer therapies, focusing primarily on the development of its principal drug candidate, Belinostat. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within peripheral T-cell lymphoma (PTCL) and phase II in cancer of unknown primary (CUP). It works in partnerships with Spectrum Pharmaceuticals Inc., Multimeric Biotherapeutics Inc. and the National Cancer Institute. As of December 31, 2011, the Company had five wholly owned subsidiaries, namely Topotarget UK Limited, Topotarget Germany AG, Topotarget USA Inc., Topotarget Switzerland S.A. and Topotarget Netherlands B.V. The Company’s two largest shareholders are HealthCap funds and Avanza bank. In April 2014, combined holdings of Topotarget A/S shares for all relevant HealthCap entities (HealthCap III and HealthCap IV) were reduced below 10%.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201412/31/2013Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Independent Chairman of the Board Bo J.Hansen 63 8/30/2012 7/23/2009
Director of Finance LoneDahl 53
Director of Pharmaceutical Operations Elisabeth V.Carstensen 51
7 additional Officers and Directors records available in full report.

Business Names
Business Name
TOPO
Topotarget A/S

General Information
Number of Employees: 12 (As of 3/31/2014)
Outstanding Shares: 145,791,112 (As of 7/2/2014)
Shareholders: 8,528
Stock Exchange: CPH


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023